Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.3 CAD | 0.00% | +1.86% | +0.87% |
May. 17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
May. 17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 35M 25.39M | Sales 2025 * | 38.7M 28.07M | Capitalization | 110M 79.53M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.13 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.83 x |
P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
14.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.63% |
Latest transcript on BioSyent Inc.
1 week | +1.86% | ||
Current month | +2.76% | ||
1 month | +9.41% | ||
3 months | +8.14% | ||
6 months | +7.89% | ||
Current year | +0.87% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 9.3 | 0.00% | 2 584 |
24-06-10 | 9.3 | +1.31% | 1,209 |
24-06-07 | 9.18 | +0.33% | 800 |
24-06-06 | 9.15 | -1.61% | 810 |
24-06-05 | 9.3 | +1.86% | 1,735 |
Delayed Quote Toronto S.E., June 11, 2024 at 09:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.87% | 79.68M | |
+46.66% | 779B | |
+40.50% | 631B | |
-6.90% | 354B | |
+19.96% | 333B | |
+9.85% | 301B | |
+16.92% | 249B | |
-1.76% | 216B | |
+10.72% | 214B | |
+4.60% | 163B |
- Stock Market
- Equities
- RX Stock